Sakeena Itoo reviews performance, functioning of JKMSCL

JAMMU: Minister for Health and Medical Education, Social Welfare and Education, Sakeena Itoo today emphasized on stricter quality checks and greater accountability in the procurement and supply of medicines and medical equipments for Health facilities across Jammu and Kashmir, asserting that patient safety remains government’s top priority.

The Minister made these remarks while chairing a high-level review meeting at Civil Secretariat here to assess the performance and functioning of Jammu & Kashmir Medical Supplies Corporation Limited (JKMSCL).

The meeting was attended by Commissioner Secretary, Health and Medical Education (H&ME), M Raju; MD NHM, Akriti Sagar; MD JKMSCL, Tariq Hussain Ganie; Director SKIMS, Prof M. Ashraf Ganie; Director Finance H&ME, Director Planning H&ME, Director Health Services Kashmir/Jammu, Principals of all GMCs, Principal Dental College Srinagar/Jammu, State Drug Controller, Medical Superintendents of all Hospitals, Chief Medical Officers and other concerned officers attended the meeting, either in person or through video conferencing.

Addressing the officers during the meeting, the Minister underlined the impact of the corporation’s responsibilities, stating that JKMSCL plays a vital role in the public healthcare delivery system by ensuring timely availability of medicines, surgical consumables and medical equipment in government health institutions. “Any compromise in quality, transparency or efficiency will not be tolerated, as it directly affects patient safety and credibility of the public health system”, she maintained.

While reviewing quality control measures and other protocols, the Minister instructed the MD to maintain constant checks on the quality of medicines and equipment procured by the Corporation. “Tighten quality control protocols at every stage, from procurement and testing to storage and final distribution”, she said.

The Minister further instructed the corporation to ensure that only certified, safe and standard-compliant medicines and equipment reach government hospitals, warning that any negligence in quality verification will invite strict action.

“Conduct regular quality audits, enhanced laboratory testing and strict vendor scrutiny so that suppliers adhere fully to prescribed standards and contractual obligations”, the Minister maintained.

While reviewing procurement procedures, supply chain management, inventory status, vendor performance and existing quality testing mechanisms of the corporation, the Minister directed the MD to take action against firms/vendors delaying supply of essential drugs or medical equipment. She also sought a detailed report from the Corporation on action taken since 2021 against ill-performing firms/vendors.

Source: Kashmir Vision

Related Posts

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

The Team Meticulously averted the Risk of Thrombosis, Husband was Donor Delhi/NCR : Doctors at Yashoda Medicity have successfully performed a high-risk kidney transplant in a 28-year-old woman with Antiphospholipid…

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

Avacta, a UK-based clinical stage biotech, is differentiated clinical-stage oncology specialist, increasingly defined by continuing progress with its second-generation pre|CISION tumour-activated Peptide Drug Conjugate (PDC) platform. The lead Gen Two…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

Puresta launches EVERQ, AI-powered skin-health platform

Puresta launches EVERQ, AI-powered skin-health platform

Stem cell therapy for autism only in approved clinical trials: Centre

Stem cell therapy for autism only in approved clinical trials: Centre